Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor Cohort (VIPER)

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07770022
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

The purpose of this study is to better understand the biological changes associated with Long COVID and to identify laboratory tests (biomarkers) that may help diagnose the condition and measure how it changes over time. Researchers will enroll people with Long COVID as well as people who have fully recovered after COVID-19 infection. Participants will provide health information and biological samples, such as blood, saliva, stool, and, for some participants, tissue biopsies. These samples will be used to study the biological processes involved in Long COVID and to support the development of new diagnostic tests that may improve future research, clinical trials, and patient care.

Key Dates

First listed
Aug 18, 2026
Start date
May 18, 2026
Status verified
Aug 2026
Primary completion
May 15, 2031
Completion
May 15, 2031

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: Long COVID
    People experiencing Long COVID symptoms
  • Arm: Recovered
    People who have fully recovered from their COVID infection(s)

Primary Outcome Measure

Participant age [ Time Frame: Baseline visit ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Zuckerberg San Francisco General HospitalSan FranciscoCalifornia94110
Lynn Ngo, MPH
[email protected]
(415) 322-8432
Michael Peluso (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

Nationwide
COVID-19 / long COVID trialsInfectious disease trials
By condition
COVID-19 / long COVID
By specialty
Infectious disease
By research site
Zuckerberg San Francisco General Hospital· San Francisco, CA

Related Studies